TEVA PHARMACEUTICAL INDUSTRIES LIMITED Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest of $27.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest · last filed 2026-07-29
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $27.00M, a 0.00% change year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $0.00.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was $27.00M, a 35.71% decline year-over-year.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 9 month |
|---|---|---|---|
| 2026-03-31 | $27.00M 10-Q · filed 2026-04-29 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-07-29 | $27.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $27.00M 10-Q · filed 2026-07-29 | |
| 2025-03-31 | $27.00M 10-Q · filed 2025-05-07 | ||
| 2024-09-30 | -$68.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$36.00M derived: sum of 2 quarters · filed 2025-11-05 | $6.00M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $32.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $74.00M 10-Q · filed 2025-07-30 | |
| 2024-03-31 | $42.00M 10-Q · filed 2025-05-07 | ||
| 2023-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $75.00M derived: sum of 2 quarters · filed 2024-11-06 | $84.00M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $60.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $69.00M 10-Q · filed 2024-07-31 | |
| 2023-03-31 | $9.00M 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | $43.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $193.00M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $150.00M 10-Q · filed 2023-08-02 |